DFTX logo

DEFINIUM THERAPEUTICS INC

DFTXNASDAQ
🏆 #1300 by market capEarnings Nov 4US Equity
$606.29▲ $6.91 (+1.14%)
Simulated price
🔔
Track DFTX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.1%
7d▲ 1402.9%
14d▲ 1546.6%
30d▲ 1378.8%
ytd▲ 4426.2%
1y▲ 4939.8%
🏦Market Cap
$5.12B
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Weak

Trading Snapshot

Day Range
$597.55 – $618.21
52-Week Range
$12.88 – $49.20
Volume
$2.51B
Avg Volume
$2.37B
Shares Outstanding
132.7M
Next Earnings
Dec 16, 2026

Fundamentals Snapshot

Annual Revenue
$457M
Last Q Revenue
$112M
P/E Ratio
-11.2
P/S Ratio
0.0x
EPS (TTM)
$-3.20
Dividend Yield
0.00%
Dilution (1yr)
+6.4%

Why Investors Own DFTX

  • ✓High-growth profile — revenue up +56.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 58% gross margin and 12% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

DFTX logo

DEFINIUM THERAPEUTICS INC

DFTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$166M▲ +60.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$132M▲ +66.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
89.3M▲ +6.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$258M▲ +$6M YoY
StockOtter · stockotter.space

About DEFINIUM THERAPEUTICS INC

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Ratings

ⓘ
Consensus
Buy
24 analysts
Strong Buy9
Buy14
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
Bloomberg·2h ago

DEFINIUM THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift DFTX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

DEFINIUM THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.